Compare DX & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DX | HRMY |
|---|---|---|
| Founded | 1987 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.2B |
| IPO Year | 1994 | 2020 |
| Metric | DX | HRMY |
|---|---|---|
| Price | $9.93 | $32.74 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 12 |
| Target Price | $12.60 | ★ $48.08 |
| AVG Volume (30 Days) | ★ 5.9M | 1.0M |
| Earning Date | 10-19-2026 | 11-04-2026 |
| Dividend Yield | ★ 20.71% | N/A |
| EPS Growth | ★ 65.77 | 7.97 |
| EPS | N/A | ★ 2.63 |
| Revenue | N/A | ★ $868,453,000.00 |
| Revenue This Year | $2.39 | $18.31 |
| Revenue Next Year | $41.18 | $14.97 |
| P/E Ratio | ★ N/A | $12.53 |
| Revenue Growth | N/A | ★ 21.51 |
| 52 Week Low | $9.60 | $25.90 |
| 52 Week High | $14.93 | $43.49 |
| Indicator | DX | HRMY |
|---|---|---|
| Relative Strength Index (RSI) | 34.28 | 32.34 |
| Support Level | N/A | $32.53 |
| Resistance Level | $11.17 | $34.16 |
| Average True Range (ATR) | 0.30 | 1.44 |
| MACD | -0.05 | -0.06 |
| Stochastic Oscillator | 19.59 | 4.78 |
Dynex Capital Inc is a real estate investment trust (REIT) focused on delivering dividends supported by long term returns from investments in mortgage assets backed by U.S. housing and commercial real estate. The Company is internally managed and mainly invests in residential and commercial mortgage-backed securities (RMBS and CMBS), which are Agency securities guaranteed by U.S. government-sponsored enterprises (GSEs). It manages interest rate, prepayment, spread, liquidity, and counterparty risks and operates through one reportable segment investing in MBS funded with repurchase agreements and equity.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.